About spruce biosciences inc - SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
SPRB At a Glance
Spruce Biosciences, Inc.
611 Gateway Boulevard
South San Francisco, California 94080
| Phone | 1-415-655-4168 | Revenue | 4.91M | |
| Industry | Biotechnology | Net Income | -53,036,000.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SPRB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.529 |
| Price to Book Ratio | 0.615 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.333 |
| Enterprise Value to Sales | -3.799 |
| Total Debt to Enterprise Value | -0.148 |
SPRB Efficiency
| Revenue/Employee | 233,857.143 |
| Income Per Employee | -2,525,523.81 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.066 |
SPRB Liquidity
| Current Ratio | 2.90 |
| Quick Ratio | 2.90 |
| Cash Ratio | 2.542 |
SPRB Profitability
| Gross Margin | 99.063 |
| Operating Margin | -1,143.372 |
| Pretax Margin | -1,079.943 |
| Net Margin | -1,079.943 |
| Return on Assets | -71.115 |
| Return on Equity | -100.704 |
| Return on Total Capital | -167.91 |
| Return on Invested Capital | -97.38 |
SPRB Capital Structure
| Total Debt to Total Equity | 9.594 |
| Total Debt to Total Capital | 8.754 |
| Total Debt to Total Assets | 6.116 |
| Long-Term Debt to Equity | 2.984 |
| Long-Term Debt to Total Capital | 2.723 |